BLR 400
Alternative Names: BLR-400Latest Information Update: 31 Mar 2023
At a glance
- Originator BLR Bio
- Class Peptides; Skin disorder therapies
- Mechanism of Action Fibroblast activation protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hypertrophic scars; Megalodactyly; Scars
Most Recent Events
- 20 Mar 2023 Preclinical trials in Hypertrophic scars in USA (unspecified route) (BLR Bio pipeline, March 2023)
- 20 Mar 2023 Preclinical trials in Megalodactyly in USA (unspecified route) (BLR Bio pipeline, March 2023)
- 20 Mar 2023 Preclinical trials in Scars in USA (unspecified route) (BLR Bio pipeline, March 2023)